Dompé Farmaceutici S.p.a
Clinical trials sponsored by Dompé Farmaceutici S.p.a, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drops aim to soothe dry eye sufferers Results expected Jan 2027 (estimated)
- New eye drops aim to stop itching and eye damage from severe allergies Results expected Mar 2027 (estimated)
- Nasal spray could reverse sudden blindness in groundbreaking trial Results expected Sep 2027 (estimated)
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control Stopped earlyThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase 2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control Stopped earlyThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in 414 hospitalized adults with COVID-19 or other pneumonia. The trial was stopped early. Researchers compared reparixin to a placebo to see if it reduced severe ou…
Phase 3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Sjögren's dry eye study probes corneal nerve damage
Knowledge-focused Stopped earlyThis study aimed to find out how many people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. The study w…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC